Insight, China's Pharmaceutical Industry

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its iza‑bren, a first‑in‑class EGFR×HER3 bispecific antibody‑drug...

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026

The U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the...

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026

Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ: ACLX) for USD 115.00...

Company

Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry

Fineline Cube Feb 24, 2026

Pfizer Inc. (NYSE: PFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd....

Company

Merck Restructures Human Health into Oncology and Specialty Units – Appoints Oosthuizen and Foard to Lead New Divisions

Fineline Cube Feb 24, 2026

Merck & Co. (MSD, NYSE: MRK) announced a major organizational restructuring of its Human Health division,...

Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category 1 innovative humanized anti‑PD‑L1 monoclonal antibody...

Company Drug

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Fineline Cube Feb 14, 2026

Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved...

Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026

Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding...

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026

Siemens Healthineers AG (ETR: SHL) and Mayo Clinic announced an expansion of their strategic partnership, targeting...

Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026

VivaVision Biotech (Zhejiang) Co., Ltd., an ophthalmology-focused biotech company founded in 2016, has submitted its...

Medical Device

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY

Fineline Cube Feb 14, 2026

Astellas Pharma Inc. (TYO: 4503) announced that its VENTANA CLDN18 (43-14A) Assay has received approval...

Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026

Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with...

Company Drug

3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Feb 14, 2026

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), announced that...

Company Drug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

Fineline Cube Feb 13, 2026

Bio-Thera Solutions Inc. (SHA: 688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its...

Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026

First Imaging, a Nantong-based medical imaging equipment provider, has closed a Series B+ financing round...

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

Fineline Cube Feb 13, 2026

CARsgen Therapeutics Holdings Ltd. (HKG: 2171), a China-based CAR-T cell therapy specialist, announced plans to invest...

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Fineline Cube Feb 13, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...

Company Medical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

Fineline Cube Feb 13, 2026

Novocure Ltd. (NASDAQ: NVCR), Zai Lab Ltd.’s (NASDAQ: ZLAB, HKG: 9688) Swiss oncology partner, announced FDA clearance for...

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026

China Medical System Holdings Limited (HKG: 0867) announced a licensing agreement with Teikoku Seiyaku Co., Ltd.,...

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Fineline Cube Feb 13, 2026

Organon & Co. (NYSE: OGN) announced fourth quarter and full-year 2025 financial results, with total revenue...

Insight, China's Pharmaceutical Industry

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry

Merck Restructures Human Health into Oncology and Specialty Units – Appoints Oosthuizen and Foard to Lead New Divisions

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

You Missed

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib

NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China